（编辑 袁冠琳） 证券日报网讯 新天药业9月30日在互动平台回答投资者提问时表示，公司已于2024年7月26日披露了终 止发行股份购买资产事项的公告，具体内容详见公司已发布的相关公告。但打造行业领先的综合性医药 企业仍是公司的长期发展战略。 ...

证券日报网讯新天药业（002873）9月29日在互动平台回答投资者提问时表示，公司持续增加对汇伦医 药的投资是基于公司中长期发展规划目标所做出的审慎决策。汇伦医药作为一家聚焦于重大疾病和危重 症治疗领域的创新型医药企业，具备较强的小分子化药创新研发能力。通过增加对汇伦医药的投资，加 大公司在小分子化药领域的投入，有利于进一步提升公司未来的市场竞争力，加速打造公司实现行业领 先的综合性医药企业战略目标。 ...

证券代码：002873 证券简称：新天药业 公告编号：2025-054 贵阳新天药业股份有限公司 关于对参股公司增资并受让其部分股权暨关联交易 的进展公告 一、对参股公司增资并受让其部分股权暨关联交易概述 贵阳新天药业股份有限公司（以下简称"公司"）于2025年8月21日召开了第 八届董事会第二次会议，审议通过了《关于对参股公司增资并受让其部分股权暨 关联交易的议案》，同意公司使用自有资金4,000万元以"增资+受让"方式，增 加对参股公司上海汇伦医药股份有限公司（以下简称"汇伦医药"）的股权投资， 其中：以2,000万元对汇伦医药进行增资，增资对应可获得汇伦医药股份235.2941 万股；以2,000万元受让湖北苹湖创业投资有限公司（以下简称"苹湖创投"） 持有的汇伦医药股份235.2941万股（以下将增资事项及受让汇伦医药部分股权合 称为"本次交易"）。同时参与汇伦医药本次增资的还有新增股东烟台天自汇莱 创业投资基金合伙企业（有限合伙）增资3,700万元，新增股东北京金慧丰投资 管理有限公司增资1,500万元，各主体本次增资合计7,200万元，增资价格均为人 民币8.5元/股。参与汇伦医药本次增资的各投资 ...

Company Overview - Xintian Pharmaceutical Co., Ltd. is located in Guizhou Province, established on August 11, 1995, and listed on May 19, 2017. The company specializes in the research, production, and sales of traditional Chinese medicine [1] - The main business revenue composition includes gynecological products (74.16%), urological products (17.04%), heat-clearing and detoxifying products (7.79%), and others (1.01%) [1] Stock Performance - As of September 17, the stock price of Xintian Pharmaceutical decreased by 2.06%, trading at 11.41 CNY per share, with a total market capitalization of 2.785 billion CNY [1] - Year-to-date, the stock price has increased by 21.72%, but it has seen a decline of 0.35% over the last five trading days and a 16.53% drop over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on August 20, where it recorded a net purchase of 56.32 million CNY [1] Financial Performance - For the first half of 2025, Xintian Pharmaceutical reported a revenue of 358 million CNY, a year-on-year decrease of 18.88%, and a net profit attributable to shareholders of 5.77 million CNY, down 80.99% year-on-year [2] - The company has distributed a total of 127 million CNY in dividends since its A-share listing, with 61.87 million CNY distributed over the past three years [3] Shareholder Information - As of September 10, the number of shareholders decreased to 33,700, a reduction of 5.83%, while the average circulating shares per person increased by 6.19% to 7,083 shares [2] - As of June 30, 2025, the top ten circulating shareholders included a new entry, Nuoan Multi-Strategy Mixed A, holding 1.0731 million shares, while Baodao Yuanhang Mixed A exited the top ten list [3]

Group 1 - The company, New Tian Pharmaceutical, reported that as of September 10, 2025, the number of shareholders is 33,696 [2]

Group 1 - Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd. has been established with a registered capital of 10 million yuan [1] - The company's business scope includes elderly care services, remote health management services, medical research and experimental development, as well as engineering and technology research and experimental development [1] - The company is wholly owned by Xintian Pharmaceutical (002873) [1]

Group 1 - The company, New Tian Pharmaceutical, reported that as of August 29, 2025, the number of shareholders is 35,781 [2]

Core Viewpoint - Guizhou Xintian Pharmaceutical Co., Ltd. has established a wholly-owned subsidiary, Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd., with an investment of 10 million RMB to enhance its health food production and sales capabilities [2] Company Overview - Guizhou Xintian Pharmaceutical was founded on August 11, 1995, with a registered capital of 2,441.03806 million RMB [2] - The company specializes in the research, production, and sales of traditional Chinese medicine [2] - The current chairman is Dong Dalun, and the company employs 1,682 people [2] Business Strategy - The new subsidiary will focus on health food production, food sales, and health consulting services [2] - The investment aligns with the company's strategic development plan and aims to diversify its product matrix and improve operational scale and profitability [2] Financial Performance - Projected revenues for 2024 and Q2 2025 are 858 million RMB, 193 million RMB, and 358 million RMB, with year-on-year changes of -10.11%, 8.93%, and -18.88% respectively [3] - The net profit attributable to the parent company for the same periods is projected to be 52.3229 million RMB, 4.1875 million RMB, and 5.7661 million RMB, with year-on-year declines of -35.30%, -73.11%, and -80.99% respectively [3] - The company's asset-liability ratios for the same periods are 38.75%, 37.48%, and 37.03% [3] Risk Factors - The company has 31 internal risk alerts and 38,039 external risk alerts, indicating a significant level of risk exposure [3]

Group 1 - The company announced that its wholly-owned subsidiary, Shanghai Shuo Fang Pharmaceutical Technology Co., Ltd., received a patent for a method to detect the fingerprint spectrum of ginkgo biloba decoction [1] - The acquisition of this patent is expected to enhance the company's intellectual property protection system and strengthen its core competitiveness through continuous innovation [1] - The company specializes in the research, development, production, and sales of traditional Chinese medicine, focusing on gynecological and urological medications, among other areas [1][2] Group 2 - The company adheres to a philosophy of combining traditional formulas with modern technology to improve clinical efficacy, ensuring a comprehensive approach to drug development [2] - The company’s product lineup includes unique varieties that cover multiple therapeutic areas, with a strong emphasis on clinical efficacy and inclusion in national basic drug and medical insurance directories [3] - The leading products, such as Kuntai capsules and Ningpitai capsules, are recognized as unique patented varieties with significant market barriers and pricing advantages [3] Group 3 - In the first half of 2025, the company achieved a revenue of 358 million yuan and a net profit of 5.77 million yuan attributable to shareholders [4]

证券日报网讯 9月3日晚间，新天药业发布公告称，公司的全资子公司上海硕方医药科技有限公司于近 日收到国家知识产权局颁发的一项发明专利证书，名为"一种检测白果水煎液指纹图谱的方法及其指纹 图谱"。 （文章来源：证券日报） ...